National Institutes of Health

InVivo Biosystems develops and commercializes proprietary systems for genetic modification of non-mammalian model organisms like C. elegans and zebrafish. Their platform enables researchers worldwide to create custom models for aging, developmental, and disease studies, accelerating drug discovery and understanding human health.

Invizyne specializes in the design of enzymes and construction of cell-free enzymatic pathways for continuous, unassisted biomanufacturing outside living cells.

GreenMark Biomedical Inc. is a minimally invasive healthcare company focused on developing innovative technologies utilizing biopolymer nanoparticles derived from natural starch. Founded in 2016 and based in East Lansing, Michigan, with a laboratory in Ann Arbor, the company specializes in dental and medical applications. Its dental technologies include a mouth rinse product that illuminates cavities and early-stage lesions, allowing dentists to accurately diagnose and treat tooth decay. Additionally, GreenMark's medical technologies are designed for targeted delivery of anti-cancer drugs, enhancing treatment precision. The company aims to provide health benefits through its advanced nanoparticle-based solutions, promoting less invasive and more effective healthcare practices.

Myosin Therapeutics is a biopharmaceutical company focused on developing novel medications that target cellular motor proteins. It leverages molecular machines that convert energy into mechanical work inside cells to create therapies aimed at treating central nervous system disorders and other diseases, including cancer. The company concentrates on advancing pharmacotherapies that modulate motor protein activity to impact disease pathways and address significant unmet medical needs.

Neuronoff is a medical device company focused on developing the Injectrode, an injectable metal electrode delivered through a small needle to create neuromodulation interfaces inside the body across various targets. The platform aims to simplify complex neuromodulation surgeries into outpatient procedures and enables electrical stimulation of hard-to-reach anatomical targets using wired or wireless energy transfer to restore and improve organ activity.

Vast Therapeutics, Inc. is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Established in 2017 and previously known as Novoclem Therapeutics, the company aims to address chronic infections that are prevalent in the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing its innovative therapeutic solutions to improve health outcomes for patients facing these challenging conditions.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Rhealth is a biotechnology company that develops AI-powered health management solutions for hospitals, offering a platform that delivers comprehensive health information to clinicians and patients and integrates portable diagnostics and monitoring capabilities to support timely, data-driven care.

BMI OrganBank develops innovative medical devices and perfusion technology to enhance organ and tissue preservation for transplantation. The company collaborates with academic institutions to expand the possibilities of organ transplantation, aiming to improve patient outcomes.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm specializes in creating unique and transformative medicines that specifically target brain-related conditions. Sparian is committed to advancing therapeutic solutions that address both acute and chronic pain through cutting-edge science and novel drug discovery methods.

Novel Microdevices, LLC is a medical device company that specializes in the development of handheld devices for molecular diagnostics. Founded in 2014 and headquartered in Annapolis, Maryland, the company has created the NOVEL DX device, which employs microfluidics technology to analyze raw biological samples at the point of care. This device delivers results in approximately 30 minutes, allowing healthcare professionals to achieve lab-quality diagnostics without the need for a traditional laboratory setting. Novel Microdevices caters to various sectors, including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture, thus addressing a wide range of applications in health and safety.

Young Heart Valve is a Polymeric, Hyaluronan-Enhanced Transcatheter Aortic Valves which were developed by engineers with inspiration from nature. The future of heart valve intervention is being altered by Young Heart Valve. Animal tissue is no longer required thanks to Young Heart Valve. Hyaluronan is included into the leaflets of Young Heart Valve's RejuvenateTM TAVR device, forming a biomolecular interpenetrated network that has been shown to be resistant to calcification and thrombosis.

Brixton Biosciences is a clinical-stage life sciences company developing therapies for pain management. The company focuses on non-addictive, locally targeted treatments delivered via a drug-free injectable that produces reversible nerve inhibition, aiming to provide long-lasting relief. Its lead approach seeks to extend pain relief from a single injection to thirty to sixty days, reducing reliance on systemic medications and addressing unmet needs in both chronic and acute pain.

ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

Teal Health specializes in developing at-home cervical cancer screening devices, aiming to enhance convenience, privacy, and accessibility for women. Their FDA-approved platform includes a sampling device, virtual consultations with licensed providers, secure laboratory testing, an online results portal, and coordination of follow-up care.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

CytoAgents is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products for treating life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation.

Resvita Bio develops and manufactures engineered probiotics for treating skin-related diseases, including cancer. Leveraging a synthetic biology platform, the company uses genetically engineered bacteria to produce and deliver therapeutic proteins directly to affected skin areas, providing continuous treatment and addressing limitations of traditional therapies. It targets conditions such as Netherton Syndrome and Severe Atopic Dermatitis, pursuing novel methods to manage skin disorders through localized, sustained protein delivery.

Cenna Biosciences is a biosciences company focused on the discovery and development of innovative drugs aimed at preventing and treating Alzheimer's disease. The company employs a proprietary mechanism to address the underlying cause of the disease, specifically targeting the inappropriate deposition of toxic ß-amyloid species in the brains of affected patients. Cenna Biosciences has identified a novel target and is actively developing several lead peptide compounds as disease-modifying candidates for Alzheimer's treatment.

Tiziana Life Sciences is a UK-based clinical-stage biotechnology company focused on discovering and developing novel molecules to treat diseases in oncology and immunology. Its pipeline includes Foralumab for autoimmune and inflammatory diseases, Milciclib for hepatocellular carcinoma, Anti IL-6r for severe COVID-19 symptoms, and StemPrintER for breast cancer diagnosis.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Evoq Therapeutics is a biotechnology company that develops immunotherapies intended to restore immune tolerance in autoimmune diseases. Its proprietary nanodisc platform delivers disease-specific antigens to modulate immune responses, with NanoDisc constructs designed to train the immune system to tolerate targeted proteins while preserving overall immunity. The approach has shown activity in preclinical models of autoimmune conditions including celiac disease, type 1 diabetes, lupus, pemphigus, Graves’ disease, and rheumatoid arthritis, among others. Through these nanodisc-based therapies, Evoq Therapeutics aims to provide treatment options that reduce pathological immune activity and improve patient outcomes without broad immunosuppression.

Ensysce Biosciences is a clinical-stage biotechnology company developing safer prescription drugs using proprietary platforms. It focuses on creating abuse-resistant opioids and overdose-protection products to reduce addiction risks and accidental overdoses associated with traditional opioids.

Unlocked Labs develops targeted probiotics designed to manage specific health conditions. Their first product focuses on reducing kidney stone risk by digesting a stone-forming compound found in healthy foods like leafy vegetables.

Penderia Technologies is a medical device company focused on innovative orthopedic solutions. It develops implantable, battery-less sensors for monitoring injury and healing progress in real-time, enabling personalized rehabilitation therapies.

Marker Therapeutics is a clinical-stage immuno-oncology company developing adoptive non-gene modified T cell therapies for treating hematologic malignancies. Its MultiTAA technology selectively expands non-engineered T cells to target and kill tumor cells expressing multiple tumor-associated antigens, preventing immune escape.

Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. It develops and commercializes innovative diagnostic tools using its proprietary technology platform, IMMray, which is based on antibody microarray analysis. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests. By collaborating with medical institutions and research centers worldwide, Immunovia aims to bring its diagnostic solutions to market, significantly impacting the treatment and management of pancreatic cancer and potentially improving survival rates. Its approach to utilizing blood-based biomarkers may also enable early detection strategies for other cancers and autoimmune diseases.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for cannabinoid overdose and substance addiction. Its lead candidate, ANEB-001, is designed to reverse the effects of cannabinoid overdose within about one hour of administration. Early clinical data indicate rapid absorption and tolerability, with weight loss observed potentially linked to central cannabinoid receptor type 1 antagonism. The company aims to address acute overdose symptoms such as sedation, anxiety, panic, and psychosis by restoring balance to the endocannabinoid system.

VenoStent develops bioabsorbable smart polymer wraps for vascular surgeries. Its flagship product, SelfWrap, is a perivascular wrap designed to reduce failures at the vein-artery junction in dialysis patients by promoting outward vein growth and providing custom-fit mechanical support. The company's technology acts as an external stent, reducing surgery time, infection risk, and wound reopening while improving vein usability and durability.

Metabolon develops metabolomics-based platforms and clinical diagnostic tests for early disease detection and precision medicine. It offers blood tests like QUANTOSE IR and QUANTOSE IGT, and Meta IMD for inherited metabolic disorders. The company serves various sectors including academia, biotech/pharmaceuticals, and precision medicine. It has strategic partnerships with major pharmaceutical companies and other industries.

Ensysce Biosciences is a clinical-stage biotechnology company developing safer prescription drugs using proprietary platforms. It focuses on creating abuse-resistant opioids and overdose-protection products to reduce addiction risks and accidental overdoses associated with traditional opioids.

Matter Bio is a biotechnology company dedicated to preserving genomic integrity. It offers research services aimed at enhancing longevity by safeguarding and utilising DNA information. The company's primary focus is assembling an elite team of scientists and executives to combat genetic mutations and extend patient lifespan through innovative approaches to reverse such mutations.

Nanopath is a molecular diagnostics company that develops innovative platforms for rapid disease diagnosis. Its technology enables point-of-care testing, eliminating the need for nucleic acid amplification and supporting multiplexed detection. This allows patients and healthcare providers to access accurate diagnostic results within standard office visits, improving healthcare outcomes.

Founded in 2017, Phenomix Sciences is a biotechnology company specializing in metabolomics and genomics. It develops precision medicine tools for chronic disease management, focusing on obesity. The company's AI-driven platform offers a novel blood test to classify patients' unique pathophysiological phenotypes, enabling personalized treatment with improved efficacy and fewer side effects.

Selsym Biotech is a biotechnology company developing platelet-mimetic therapies and hemostatic technologies to control bleeding in trauma, surgery, and wound care. The company’s approach combines biomimetic platelet-inspired mechanisms with innovative materials such as Hemostatic Healing Hydrogels (H3) to promote rapid hemostasis and tissue repair. By addressing ongoing platelet supply shortages and shelf life challenges, Selsym Biotech aims to provide readily available, effective bleeding management solutions for emergency and surgical settings. The firm focuses on enabling healthcare providers to manage hemorrhage more effectively, reduce transfusion needs, and improve patient outcomes through therapies that mimic native platelet function and enhance wound healing.

Lamassu Pharma is a biotech startup developing small-molecule therapies for severe acute pancreatitis, with a lead candidate developed at Mayo Clinic that has shown strong preclinical results in reducing mortality and morbidity. The company is advancing this compound through safety testing in preparation for definitive clinical trials, aiming to deliver life-saving treatments to patients. In addition, Lamassu develops other small-molecule therapeutics targeting urgent medical needs, including potential cancer treatments, pursuing multiple candidates through clinical development. The organization emphasizes a patient-centric, evidence-based research approach to accelerate translation of science into therapies for unmet medical needs.

Springbok Analytics offers an AI-powered software platform that transforms MRIs into three-dimensional analyses of muscle to enable true precision. Springbok Analytics' advanced imaging technology identifies and measures each individual muscle, providing data to scientists, physical therapists, athletic trainers, and physicians to evaluate muscle function in relation to performance and injury management. The technology has numerous applications, including injury management, performance enhancement, and the treatment of musculoskeletal conditions.

Maxim Biotech provides vitro diagnostic testing development and testing solutions.

AcuraStem is a biotechnology company based in Monrovia, California, founded in 2016. The company specializes in developing a precision medicine platform that utilizes complex cellular models derived from Amyotrophic Lateral Sclerosis (ALS) patients' cells. AcuraStem employs advanced cellular reprogramming and artificial intelligence technologies to create patient-specific treatments for neurodegenerative diseases. Their platform is designed to evaluate disease progression and test existing therapeutics, as well as combinations of therapeutic approaches, to identify effective treatments that could slow disease progression. The company's team includes PhDs, professors, tech entrepreneurs, and veterans from the drug industry, all working towards addressing the challenges posed by ALS.

InVivo Biosystems develops and commercializes proprietary systems for genetic modification of non-mammalian model organisms like C. elegans and zebrafish. Their platform enables researchers worldwide to create custom models for aging, developmental, and disease studies, accelerating drug discovery and understanding human health.

RNAConnect specializes in developing enzymatic tools for visualizing and manipulating RNA, with a focus on low-abundance and long, structured RNAs. Their core product is a reverse transcriptase designed to provide greater visibility into these challenging RNA types and their various isoforms. This enzyme is optimized to synthesize cDNA with high fidelity and processivity, enabling researchers to study complex RNA template structures without the need for heat.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

Orlance provides more effective therapeutic and preventive vaccines for a wide spectrum of viral targets.

Hillhurst Biopharmaceuticals specializes in developing innovative, liquid therapeutic gases for treating sickle cell disease. Their core technology enables the oral delivery of low-dose carbon monoxide, targeting the protective heme oxygenase system to reduce inflammation, prevent cell death, and halt hemoglobin polymerization. This approach addresses challenges associated with traditional inhaled gas therapies, such as caregiver exposure and imprecise dosing, ensuring accurate and safe administration.

Endomimetics develops bio-nanometric coating technology for stents, aiming to enhance care for patients with kidney disease. Its innovative coating mimics human tissue, reducing complications and surgeries associated with implanted devices.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company offers a range of preclinical and toxicology services, utilizing advanced technologies such as quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans. L2P Research Labs also provides proprietary orthotopic and metastatic tumor models, enabling researchers to access a complete suite of research services tailored to their needs. Through its innovative approaches and state-of-the-art facilities, the company supports the advancement of scientific research in the fields of medicine and drug development.

RevBio is a biotechnology company focused on developing innovative solutions for bone repair. Its flagship product, Tetranite, is an injectable, self-setting, osteoconductive bone adhesive biomaterial designed to bond bone to bone and bone to metal in challenging environments. Tetranite is currently undergoing FDA review for various applications, including oral, craniofacial, orthopedic, and neurosurgical uses. This synthetic adhesive biodegrades over time, being replaced by new bone as part of the natural bone remodeling process, thus serving as a scaffold to promote bone growth. By utilizing this unique material, RevBio aims to reduce the duration and complexity of medical procedures, facilitate more minimally invasive surgeries, and enhance patient outcomes by decreasing pain, recovery time, and overall healthcare costs. The company is actively developing a portfolio of applications tailored for both dental and orthopedic fields.

Rational Vaccines is a biotechnology company focused on developing vaccines for herpes simplex virus (HSV) and related diseases. It aims to revolutionize treatment, prevention, and diagnosis by creating rationally engineered, live-attenuated viral vaccines.

Founded in Finland in 2003, Magnasense specializes in developing and manufacturing lateral flow tests for various applications. These include human health, environmental analysis, and veterinary testing. The company's innovative magnetic labeling technique enables quantitative measurements, enhancing reliability and sensitivity. Magnasense offers a Pilot Feasibility test service and operates as a subsidiary of LifeAssays AB.

Integral Molecular, Inc. is a biotechnology company headquartered in Philadelphia, Pennsylvania, specializing in the development of innovative technologies for drug discovery targeting challenging diseases such as cancer, HIV, and arthritis. The company is particularly known for its Lipoparticle technology, which enhances the identification and optimization of drugs aimed at integral membrane proteins. With over 20 years of expertise in membrane proteins and antibodies, Integral Molecular has supported more than 400 pharmaceutical and biotechnology companies in their research, medication discovery, and vaccine development efforts. The company's solutions are integral to various stages of the drug discovery process, focusing on the development of chemical compounds and antibodies.

Actinium Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for life-threatening diseases using its alpha particle immunotherapy platform. Its lead product candidates include Iomab-B, in Phase III trials as an induction agent for elderly AML patients prior to bone marrow transplant, and Actimab-A, in Phase II trials for newly diagnosed AML patients aged 60 and over.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

Omniose is a biotechnology company developing next-generation conjugate vaccines using its proprietary in vivo conjugating technology. The company focuses on creating vaccines against infectious diseases, with a current emphasis on pneumococcal conjugate vaccines for broader protection against bacterial strains.

Base Pair Biotechnologies, Inc. is a biotechnology company based in Pearland, Texas, specializing in the research, development, and discovery of aptamer affinity ligands. Established in 2012, the company offers custom aptamer development services and a catalog of ready-made aptamers. Its innovative platform incorporates novel libraries and proprietary methods for multiplexing the aptamer discovery process, allowing for efficient screening and validation. Base Pair Biotechnologies collaborates with academic, commercial, and government institutions to create advanced tools and technologies across various sectors, including diagnostics, therapeutics, animal testing, agriculture, and environmental testing. The company's expertise in aptamer research, which began in 2004, has positioned it as a leader in the field, enabling clients to obtain high-quality aptamers with reduced time and cost.

Golden Helix is a developer of bioinformatics solutions specializing in genomic data analysis, with a focus on supporting life science research and translational medicine. With over 20 years of experience, the company provides innovative cloud-based software that empowers scientists and healthcare professionals to manage, analyze, and visualize complex genomic and phenotypic data. By streamlining the annotation and filtering of variants from next-generation sequencing, Golden Helix enables biologists and researchers of varying expertise to conduct intricate analyses and produce meaningful insights from large genomic datasets without the constant need for specialized bioinformatics support.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Burst Diagnostics is a company focused on advancing at-home and point-of-care testing through innovative diagnostic solutions. It has developed a rapid antigen diagnostics platform designed to deliver automated laboratory analysis in a user-friendly format. The company specializes in a paper-based testing system that enables immediate deployment from laboratory settings to home use. This system provides comparable sensitivity and specificity to traditional laboratory ELISA tests in an accessible format resembling a lateral flow assay. Burst Diagnostics aims to enhance the capabilities of medical communities, enabling efficient testing for various conditions, including SARS-CoV-2, among others.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Greenstone Biosciences is a drug discovery platform focused on accelerating the development of effective therapies for patients. By leveraging advanced technologies, including artificial intelligence and human-induced pluripotent stem cells, the company aims to transform the traditional drug discovery process, which is often slow and prone to high failure rates. Greenstone Biosciences seeks to create a rapid and integrated computational platform that can efficiently deliver safe and effective therapeutics, addressing diseases with significant unmet medical needs. Through its innovative approach, the company is dedicated to improving patient outcomes and advancing therapeutic options.

Spinogenix is a biopharmaceutical company focused on neurorestorative therapeutics that aim to restore brain connections and functions lost after brain injury and in neurodegenerative or psychiatric diseases. Founded in 2016 and based in San Diego, California, Spinogenix develops a new class of therapies designed to regenerate synapses and reverse declines in cognitive and motor function. The company targets direct modulation of synaptic proteins to rebuild neural connectivity, with the goal of reversing synapse loss and improving neurological outcomes. Therapies may be used as monotherapy or in combination with other treatments to address disease-specific degenerative processes, aiming to restore neural networks disrupted by CNS injury and degeneration.

Daxor Corporation is a medical device and biotechnology company based in New York, founded in 1970. It specializes in blood volume measurement, offering the BVA-100 Blood Volume Analyzer, the first FDA-approved instrument for the rapid and direct measurement of a patient's true blood volume. This device is utilized in diagnosing and managing various medical conditions, including congestive heart failure, critical care medicine, hypertension, and anemia. In addition to its core product, Daxor provides cryobanking services such as semen banking and blood storage, along with andrology and general laboratory testing services. The company also collaborates with the Uniformed Services University of the Health Sciences to research the effectiveness of its diagnostic tests in traumatic injury contexts. Daxor was previously known as Idant Corporation before rebranding in May 1973.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

National Disease Research Interchange is the source of human tissues, cells and organs for scientific research. Top 250k Enrichment Emp Range Freshness 2024 - Not Found

Founded in 2017, Nexilico is an early-stage biotechnology company based in Albany, California. It specializes in advancing microbiome and precision medicine research through the development of predictive computational platforms. These platforms aim to enhance drug design, development, and clinical outcomes for various therapeutics.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-based therapies for cancer and infectious diseases. Incorporated in 2011 and located in Winchester, Massachusetts, the company has created a platform that targets the tumor necrosis factor receptor 2 (TNFR2) oncogene and the specific population of TNFR2 regulatory T cells within the tumor microenvironment. This innovative approach aims to enhance immunotherapy strategies, particularly for chronic infectious diseases, by leveraging the body's immune system to combat various health challenges.

Curi Bio is a biotechnology company dedicated to enhancing drug discovery and development through innovative technologies that leverage human stem cells, systems biology, and data analytics. The company aims to streamline the identification and development of new medicines by providing advanced biosystem platforms that integrate human cells and data. Curi Bio's technology offers a range of products designed for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research. By enabling in vivo maturation and alignment of various cell types, the company allows drug developers to conduct more accurate safety and efficacy tests on new drug candidates, ultimately fostering the advancement of next-generation human medicines.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

Founded in 1975, Morehouse School of Medicine is a private medical school located in Atlanta, Georgia. It offers a Doctor of Medicine (MD) program with specializations in Family Medicine, Internal Medicine, Obstetrics and Gynecology, Pediatrics, Psychiatry and Behavioral Sciences, and Surgery. The school also provides master's degrees in Public Health and Biomedical Sciences. Morehouse is committed to educating minority students and reducing health disparities.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Founded in 2006, Civatech Oncology is a medical device company based in Durham, North Carolina. It specializes in developing polymer-based devices for localized low-dose-rate radiation cancer treatment. The company's patented technology enables customizable devices tailored to specific tumor types, with its first product, the CivaString, FDA-cleared for treating solid tumors.

Fesarius Therapeutics is a biotechnology company developing engineered tissue products for wound care, reconstructive surgery, and regenerative medicine. Its patented differential density hydrogel dermal matrices, such as DermiSphere, enhance healing from trauma, burns, or infection.

Applied BioMath, LLC, established in 2013 and headquartered in Concord, Massachusetts, specializes in systems biology and pharmacology services aimed at accelerating drug research and development for biotechnology and pharmaceutical companies. The company employs advanced mathematical modeling and simulation techniques to provide predictive guidance and insights throughout the drug discovery process. Its offerings include pathway model development, target and biomarker discovery, and feasibility assessments for various drug targets. Additionally, Applied BioMath conducts analyses of competitor compounds and projects drug properties and dosing for clinical phases. The firm utilizes proprietary algorithms and high-performance computational biology to optimize decision-making and mitigate risks associated with late-stage attrition in drug development. With additional offices in Cambridge and Oakland, Applied BioMath collaborates strategically with industry leaders such as Sanofi and Xilio Therapeutics to enhance its service offerings.

Novel Microdevices, LLC is a medical device company that specializes in the development of handheld devices for molecular diagnostics. Founded in 2014 and headquartered in Annapolis, Maryland, the company has created the NOVEL DX device, which employs microfluidics technology to analyze raw biological samples at the point of care. This device delivers results in approximately 30 minutes, allowing healthcare professionals to achieve lab-quality diagnostics without the need for a traditional laboratory setting. Novel Microdevices caters to various sectors, including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture, thus addressing a wide range of applications in health and safety.

Access to Advanced Health Institute is a nonprofit biotech research institute that brings together specialists, technologies, and platforms to offer accessible goods and solutions for leveraging the immune system to alleviate disease.

iMetabolic Biopharma is an early-stage precision medicine drug development company focused on obesity-related diseases. It develops therapeutics using its iPlatform technology, a platform designed to accelerate drug discovery and reduce development costs, enabling potential life-saving solutions to reach the clinic faster and more affordably.

AAVogen is a biotechnology company focused on developing gene therapies for muscle-wasting diseases. The company develops muscle-specific viral capsids and therapeutics intended to strengthen muscles and improve function in conditions such as inclusion body myositis, muscular dystrophies, myopathies, and peripheral neuropathies, with potential applications for heart failure and obesity with type 2 diabetes.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

Advent Therapeutics specializes in developing therapies for micro-orphan indications, focusing on unmet medical needs in neonatal and pediatric patient populations. Based in Lumberville, Pennsylvania.

Caeregen Therapeutics focuses on discovering and developing innovative pharmacological therapies aimed at restoring damaged tissues and protecting them by reactivating signaling pathways involved in healthy cellular development.

Co-Diagnostics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah, founded in 2013. The company specializes in the development, manufacture, and marketing of advanced diagnostic technologies that focus on the detection and analysis of nucleic acid molecules, such as DNA and RNA. In addition to creating reagents for diagnostic tests, Co-Diagnostics offers self-contained lab systems that incorporate diagnostic equipment from other manufacturers. The company also leverages its proprietary technology to design targeted tests for identifying genetic markers, which can be utilized in various industries beyond infectious diseases, while licensing these tests to specific customers.

Marker Therapeutics is a clinical-stage immuno-oncology company developing adoptive non-gene modified T cell therapies for treating hematologic malignancies. Its MultiTAA technology selectively expands non-engineered T cells to target and kill tumor cells expressing multiple tumor-associated antigens, preventing immune escape.

The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

Founded in 2021, Domus Diagnostics specializes in respiratory disease home testing services via its care diagnostics platform. The company offers affordable, user-friendly, and accurate testing kits designed to address infectious disease outbreaks promptly.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery platforms and the development of quality-of-life medicines. The company focuses on enhancing drug discovery and manufacturing through its innovative biotechnology and nanotechnology solutions. Aphios offers a range of therapeutic products aimed at health maintenance, disease prevention, and the treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-based product, and various formulations of Taxotere for cancer treatment, which aim to improve oral bioavailability and target specific cancer cells. In addition to its therapeutic offerings, Aphios develops advanced technologies such as SuperFluids for pharmaceutical manufacturing and virology testing services, contributing to the safety and efficacy of drug therapies. Founded in 1993, Aphios continues to push the boundaries of medical science with its focus on innovative solutions for complex health challenges.

National Disease Research Interchange is the source of human tissues, cells and organs for scientific research. Top 250k Enrichment Emp Range Freshness 2024 - Not Found

The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.

Sensor-Kinesis Corporation develops innovative medical devices focused on pathogen and virus detection. Founded in 2013 and based in Los Angeles, the company is advancing proprietary biosensor technology that integrates flexible micro biosensor chips with computer systems. These chips are designed to detect specific biomolecules and can be printed on various surfaces, enabling widespread application across multiple industries, including healthcare, food safety, and pharmaceuticals. By linking these sensors to smart devices, users can transmit and analyze biological signals in real time, facilitating improved health monitoring. Sensor-Kinesis aims to empower healthcare professionals and individuals with affordable, portable devices that provide enhanced detection capabilities for diseases and health-related risks, promoting better health outcomes and safety.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Founded in 1998, Second Sight is a medical device company dedicated to developing implantable visual prosthetics. Their primary product, the Argus II Retinal Prosthesis System, is designed to provide artificial vision to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa.

AivoCode Inc., established as a biotechnology company, specializes in innovative solutions for critical neurological disorders like traumatic brain injury and neurodegenerative diseases such as Alzheimer's. The company's proprietary technology revolves around unique peptides that selectively target molecular changes in affected brain regions, facilitating the delivery of various therapeutics and diagnostics. These peptides also exhibit intrinsic therapeutic properties. Notably, AivoCode's development has been solely funded through non-dilutive federal grants.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

The Indiana CTSI is dedicated to leveraging and strengthening the state’s life sciences community to achieve better health for people in Indiana.Leadership and staff at the Indiana CTSI are working to develop the best processes and resources to enable the efficient translation of scientific discoveries to patient care.Indiana CTSI programs and partnerships are designed to educate, attract and retain top research talent in the state for generations to come.

Chemeleon is a company that has developed an innovative platform technology for rapid and affordable diagnostics capable of detecting a wide array of analytes, including drugs, proteins, and viruses. Their proprietary in vitro diagnostic format delivers a colorimetric readout within minutes, visible to the naked eye, and does not require reagents, instruments, or specialized training. This decentralized testing approach empowers clinicians to extend point-of-care diagnostics and allows individuals to self-administer tests at the point of need. Chemeleon's diagnostics utilize highly selective molecular receptors combined with colorimetric nanomaterial reporters, facilitating immediate and actionable diagnoses that can significantly improve patient outcomes while reducing healthcare costs. Notably, the company developed a diagnostic for detecting beta-2-transferrin, a biomarker for Cerebrospinal Fluid leaks, resulting in substantial reductions in morbidity and healthcare expenses. With a focus on providing specificity and selectivity comparable to lab-based tests but in a fraction of the time and cost, Chemeleon's technology stands to transform healthcare accessibility, especially in resource-limited environments.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Millennial Scientific is an advanced material and manufacturing company focused on Chromatography and allied products. Our chromatography product portfolio comprises the award-winning NanoPak-C all-carbon suite of products. They deliver high-performance extraction, separation, and purification of chemicals and biochemicals serving underserved or unserved Life- and Bio-Science market segments. These products are available as bulk stationary phase media or packed in solid-phase extraction (SPE) and liquid chromatography columns. NanoPak-C is attracting customers with analysis requirements outside the current silica-based column capabilities and seeking faster, more efficient analysis while reducing laboratory costs and solvent usage. It is benefiting customers seeking next-generation performance capabilities to separate structurally similar compounds, biologics, biobetters, or biosimilars.